This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We may also share information about your use of our site with analytics partners. Read about cookies in our Cookie Policy. By clicking “Accept”, you are indicating your consent to our use of cookies and policies.

ANGITIA - INNOVATION FOR PATIENTS
Home
About Us
Pipeline
Careers
Media & News
Contact Us

INNOVATION FOR PATIENTS
About us

Founded in 2018, Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs in serious musculoskeletal diseases. With our team's experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need.

Diseases
Degenerative Disc Disease
Osteoporosis
Osteogenesis Imperfecta
Bone Metastasis
Nonunion
Osteoarthritis
Muscle Disorders
We Focus on
Musculoskeletal Diseases
More information
Careers
Become an Angitian! Angitia is a global company with a diverse team.
Our company culture revolves around respect and equality.
We are committed to fostering employee growth and career development.
More‧‧‧‧‧
Media & News
2025.09.08
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
More‧‧‧‧‧
2025.08.19
Angitia Biopharmaceuticals to Present Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
More‧‧‧‧‧
2025.06.12
Angitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2115, A Bispecific Antibody for the Treatment of Osteogenesis Imperfecta
AGA2115 also received Orphan Drug Designation from European Medicines Agency
More‧‧‧‧‧
more news...